Sunshine Biopharma, Inc. (NASDAQ: SBFM) entered into an at-the-market issuance sales agreement with Aegis Capital Corp. on July 20, 2026, allowing the company to sell up to $4,000,000 in common stock through the arrangement.

Under the agreement, Aegis Capital will act as exclusive sales agent, receiving a commission of 3.0% of gross proceeds from any shares sold. Sales may be conducted through the Nasdaq Capital Market or any other existing trading market for the company's common stock, using any method permitted under Rule 415(a)(4) of the Securities Act of 1933.

The company is not obligated to sell any shares, and the agent is not obligated to buy or sell any shares under the agreement. No assurance has been provided regarding whether any shares will be sold, or at what price or volume.

The shares will be issued under a shelf registration statement on Form S-3 filed with the Securities and Exchange Commission on January 6, 2025, and declared effective on January 15, 2025, along with a prospectus supplement filed with the SEC on July 20, 2026.

The company agreed to indemnify Aegis Capital against certain liabilities under the Securities Act and the Securities Exchange Act of 1934. Both parties retain the right to terminate the agreement under its stated terms.